Eversense and Dexcom G5: Efficacy and Accuracy in Type 1 Diabetic Patients

NACompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 14, 2018

Primary Completion Date

December 31, 2018

Study Completion Date

September 1, 2019

Conditions
Diabetes Mellitus, Type 1
Interventions
DEVICE

Dexcom G5-Eversense

Patients will wear sensor for 3 months, monitor blood capillary values 4 times/day. At the beginning and at the end of the period HbA1c will be measured and questionnaires will be administered

DEVICE

Eversense-Dexcom G5

"Patients will wear sensor for 3 months, monitor blood capillary values 4 times/day. At the beginning and at the end of the period HbA1c will be measured and questionnaires will be administered.~After 30-50 days of sensor implantation patients will wear also Dexcom G5 for a week to compare accuracy simultaneously"

Trial Locations (1)

Unknown

University of Padova, Padua

All Listed Sponsors
lead

University of Padova

OTHER

NCT03613805 - Eversense and Dexcom G5: Efficacy and Accuracy in Type 1 Diabetic Patients | Biotech Hunter | Biotech Hunter